Letrozole 2.5 mg Daily Dosing and Duration
For postmenopausal women with estrogen receptor-positive breast cancer who have completed surgery, letrozole 2.5 mg orally once daily is the standard dose, with treatment duration extending up to 10 years total of adjuvant endocrine therapy depending on nodal status and individual risk factors. 1, 2
Standard Dosing
- Dose: 2.5 mg orally once daily, taken without regard to meals 2
- This dose provides complete suppression of estradiol and estrone below quantifiable limits in postmenopausal women 3
Duration Based on Clinical Scenario
Initial Adjuvant Therapy (Years 0-5)
If letrozole is used as initial adjuvant therapy after surgery, treat for 5 years 2. The median treatment duration in pivotal adjuvant trials was 5 years 1.
Extended Adjuvant Therapy (Years 5-10)
After completing 5 years of tamoxifen:
- Node-positive disease: Strongly recommend extended letrozole for up to 5 additional years (total 10 years of endocrine therapy) 1
- Node-negative disease: May offer extended therapy based on recurrence risk, but benefits are narrower. Low-risk node-negative tumors should NOT routinely receive extended therapy 1
After completing 5 years of aromatase inhibitor: The evidence here is more nuanced. The MA.17R trial showed significant disease-free survival benefit with extended letrozole after prior AI therapy 1, while the NSABP B-42 trial showed only borderline benefit (p=0.048, not meeting the pre-specified significance threshold of 0.0418) 4. Given this mixed evidence, extended therapy after 5 years of AI should be individualized based on:
- Nodal status (node-positive favored more strongly)
- Risk of contralateral breast cancer
- Patient tolerance and bone health
Maximum Duration
Do not exceed 10 years total of adjuvant endocrine therapy 1. Treatment should be discontinued at tumor relapse 2.
Key Efficacy Data
The MA.17R trial demonstrated that letrozole 2.5 mg daily for 5 years after completing 4.5-6 years of AI therapy (most with prior tamoxifen) significantly improved disease-free survival with a hazard ratio of 0.58 (95% CI 0.45-0.76, P<0.001) 1. The NSABP B-42 trial showed a hazard ratio of 0.85 (95% CI 0.73-0.999) but did not meet the adjusted significance threshold 4.
Critical Safety Considerations
Bone Health Monitoring
- Letrozole causes median 4.1% decrease in lumbar spine bone mineral density at 24 months 1
- Monitor bone mineral density regularly during treatment 2
- Number needed to harm for bone fractures: 72 patients 1
- Absolute risk increase for fractures: 0.6-2.4% 1
Cardiovascular Risk
- Increased odds of cardiovascular events (OR 1.18,95% CI 1.00-1.40) 1
- Number needed to harm: 122 patients 1
Common Adverse Events (>20%)
- Hot flashes (38% vs 37% placebo)
- Arthralgia (53% vs 50% placebo)
- Fatigue (36% vs 37% placebo)
- Myalgia (28% vs 25% placebo) 1
Treatment Discontinuation
Approximately 21% of patients discontinue due to adverse events (NNH = 21) 1. High baseline estradiol levels are associated with increased joint and muscle pain during treatment 3.
Special Populations
Hepatic impairment with cirrhosis: Reduce dose to 2.5 mg every other day 2
Renal impairment: No dose adjustment needed if creatinine clearance ≥10 mL/min 2
Important Caveats
- No overall survival benefit has been demonstrated with extended therapy beyond 5 years 1. The recommendation is based on disease-free survival and prevention of contralateral breast cancer.
- Prevention of second primary breast cancers is a major benefit and should inform the decision to pursue extended treatment 1
- Adherence rates in clinical trials were 62-73%, indicating real-world challenges with prolonged therapy 1
- Shared decision-making weighing ongoing risks (bone fractures, cardiovascular events, quality of life impact) against absolute benefits is essential 1